A randomized, placebo-controlled, phase I/II trial of the anti-HIV activity and safety of VGX-410 (mifepristone) at three dose levels in HIV-1 infected subjects.
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Mifepristone (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 03 Feb 2010 Results were published in the Journal of Acquired Immune Deficiency Syndromes.
- 28 Sep 2008 Actual end date (May 2007) added as reported by CT.gov
- 28 Sep 2008 Status changed from active, no longer recruiting to completed as reported by CT.gov